Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | CCR6 | P51684 | 2/20 | 0.49 |
| ▸ | GALR2 | O43603 | 1/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | XBP1 | P17861 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8321809 | 0.87 | MAPT (0.54) | MAPTSMN1; SMN2POLBNPC1KDM4E | |
| SCHEMBL912582 | 0.86 | MAPT (0.59) | MAPTSMN1; SMN2POLBNPC1KDM4E | |
| SCHEMBL1313734 | 0.86 | MAPT (0.53) | MAPTSMN1; SMN2POLBNPC1KDM4E | |
| SCHEMBL9593080 | 0.86 | MAPT (0.53) | MAPTSMN1; SMN2POLBNPC1KDM4E | |
| SCHEMBL5593284 | 0.85 | OPRK1 (0.51) | MAPTPOLBNPC1KDM4ERAB9A | |
| SCHEMBL14534667 | 0.84 | MAPT (0.46) | MAPTSMN1; SMN2POLBNPC1KDM4E | |
| SCHEMBL11071021 | 0.84 | MAPT (0.53) | MAPTSMN1; SMN2NPC1KDM4ERAB9A | |
| SCHEMBL31347406 | 0.83 | MAPT (0.51) | MAPTSMN1; SMN2POLBNPC1KDM4E | |
| SCHEMBL10514547 | 0.82 | MAPT (0.50) | MAPTSMN1; SMN2POLBNPC1KDM4E | |
| SCHEMBL5486739 | 0.82 | KDM4E (0.51) | MAPTSMN1; SMN2POLBNPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8551995-B2 | (4-{6-Amino-5-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-pyridazin-3-yl}-phenyl)-morpholin-4-yl-methanone; useful in treating disorders related to abnormal protein kinase activities such as cancer | XCOVERY HOLDING COMPANY, LLC (US) | 2013-10-08 | — | — | US | disclosed |
| US-8551995-B2 | (4-{6-Amino-5-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-pyridazin-3-yl}-phenyl)-morpholin-4-yl-methanone; useful in treating disorders related to abnormal protein kinase activities such as cancer | XCOVERY HOLDING COMPANY, LLC (US) | 2013-10-08 | — | — | US | disclosed |
| US-8288540-B2 | 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors | IRM LLC (BM) | 2012-10-16 | — | — | US | disclosed |
| EP-2190836-B1 | 2-HETEROARYLAMINO-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-08-17 | — | — | EP | disclosed |
| EP-2190836-B1 | 2-HETEROARYLAMINO-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-08-17 | — | — | EP | disclosed |
| US-20110053952-A1 | 2-HETEROARYLAMINO-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | US | disclosed |
| US-20110053952-A1 | 2-HETEROARYLAMINO-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | US | disclosed |
| EP-2190836-A1 | 2-HETEROARYLAMINO-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2010-06-02 | — | — | EP | disclosed |
| US-20100063031-A1 | KINASE INHIBITOR COMPOUNDS | XCOVERY, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| US-20100063031-A1 | KINASE INHIBITOR COMPOUNDS | XCOVERY, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| US-20040224959-A1 | Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same | OHKURA NAOTO (JP) | 2004-11-11 | — | — | US | disclosed |
| US-6777414-B1 | INHIBITORS OF TRIGLYCERIDE BIOSYNTHESIS AND SECRETION OF APOLIPOPROTEIN B-CONTAINING LIPOPROTEINS; ARTERIOSCLEROTIC DISEASES; HYPERLIPIDEMIA | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-08-17 | — | — | US | disclosed |
| EP-1180514-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND BENAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | MEIJI SEIKA KAISHA LTD. (JP) | 2002-02-20 | — | — | EP | disclosed |
| EP-0133310-B1 | IMIDAZOLIDINONES, AND IMIDAZOLIDINETHIONES, PROCESS FOR THE PREPARATION THEREOF, AND USE OF SAID COMPOUNDS AS HERBICIDAL AGENTS | AMERICAN CYANAMID COMPANY (US) | 1988-09-14 | — | — | EP | disclosed |
| EP-0277661-A1 | Imidazopyrrolopyridines and condensed derivatives thereof useful in the preparation of herbicidal compounds | AMERICAN CYANAMID COMPANY (US) | 1988-08-10 | — | — | EP | disclosed |
| US-4701208-A | Dihydroimidazopyrrolopyridine, quinoline, thieno- and furo[2,3-b]pyridine, dihydrothieno- and furo[2,3-b]-pyridine, thieno- and furo[3,2-b]pyridine and dihydrothieno- and furo[3,2-b]pyridine herbicides and method for preparation thereof | AMERICAN CYANAMID COMPANY (US) | 1987-10-20 | — | — | US | disclosed |
| US-4608079-A | Imidazolidinones, and imidazolidinethiones, process and intermediates for the preparation thereof, and use of said compounds as herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1986-08-26 | — | — | US | disclosed |
| EP-0133310-A1 | Imidazolidinones, and imidazolidinethiones, process for the preparation thereof, and use of said compounds as herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1985-02-20 | — | — | EP | disclosed |
| EP-0133309-A1 | Herbicides and method for the preparation thereof | AMERICAN CYANAMID COMPANY (US) | 1985-02-20 | — | — | EP | disclosed |
| US-4053608-A | 3-NITROPYRIDINE CARBOXAMIDES, POULTRY FEED | SANKYO COMPANY LIMITED (JA) | 1977-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224959-A1 | Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same | APOB, NCEH1, LIPC | MAPT 4733/4885SMN1; SMN2 3590/4885POLB 1984/4885 |
| US-20100063031-A1 | KINASE INHIBITOR COMPOUNDS | MAP4K2, MAP3K5, MAP3K15 | MAPT 2308/4885SMN1; SMN2 3111/4885POLB 2516/4885 |
| US-20110053952-A1 | 2-HETEROARYLAMINO-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | FYN, LCK, ERBB2 | MAPT 2547/4885SMN1; SMN2 2345/4885POLB 4027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.